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Objectives: To develop an economic model that estimates the cost burden of psy-
chiatric relapse and recidivism among patients with schizophrenia after release 
from jail/prison from a US state government perspective. MethOds: A Markov 
state-transition model was developed to estimate the numbers of schizophrenia 
patients newly-released from jail/prison who would experience psychiatric relapse 
and/or arrest and re-incarceration over a period of three years, along with corre-
sponding costs. The model includes three health states: 1) in community, on therapy, 
2) in community, off therapy, and 3) incarcerated. A patient’s probability of psychi-
atric hospitalization increases with treatment discontinuation, and the probability 
of arrest increases with the risk of a psychiatric hospitalization. Data from the US 
Census and Bureau of Justice Statistics were used to estimate the model population. 
Published literature was used to estimate the risks of psychiatric relapse, arrest, 
and direct cost inputs associated with hospitalization, arrest, trial, and incarcera-
tion. Felony and misdemeanor incarceration rate and sentence length data from 
the State of Florida were applied as a base case scenario. The rate of antipsychotic 
treatment following release from jail/prison and annual risk of medication dis-
continuation were varied in sensitivity analyses. Results: Among 34,500 persons 
released from Florida state prison annually, 5,307 were estimated to have schizo-
phrenia. The estimated three-year cumulative direct costs to the state government 
were $21,146,000 and $25,616,000 for criminal justice and psychiatric hospitalization 
costs, respectively ($3,985 per patient criminal justice costs; $4,827 per patient hos-
pitalization costs). An absolute 20% increase in the proportion of patients receiving 
antipsychotic treatment following release from jail/prison decreased total cumu-
lative costs over three years by $588 per patient. cOnclusiOns: The economic 
impact of recidivism and psychiatric relapse among patients with schizophrenia is 
substantial from a state government perspective. This general model can be made 
state-specific by utilizing local criminal justice data sources.
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Objectives: It is not known the profile of the children or the economic and social 
impact of autism in Brazil. The support therapy to children with autism includes 
psychologist, speech therapist, and occupational therapy. Antipsychotics are being 
used in autism treatment. We aimed to know the profile of children with autism and 
the social and economic impact of the disease in their families. MethOds: Simple 
Internet survey conducted among Brazilian autism communities during October 
2013. We performed descriptive statistics. All monetary values are in Brazilian reais 
(BRL). Results: We obtained 48 responses. 70.8 % of autism patients were boys. The 
median age was 8 years and 54 % of the patients were between 6 and 10 years. 65 % 
of the diagnoses were made between 2 and 4 years of age. The median number of 
physicians visited to achieve diagnosis was 3, 56% of the children visited 1-3 doctors 
and 23 % had to visit more than 5 doctors. Risperidone was used by 48% of cases 
and main reported side effects were insomnia (10 %), agitation (47 %), anxiety (23 %), 
headache (7 %), and self-reported changes in eating habits (13 %). 28 % of patients 
reported some food allergy. To provide support therapy to children with autism 34 
% of families spend between 500-1500 BRL; 1500 to 2500 (19 %), 2500-3500 (17 %) 
and 2% spend 3500-4500. In 13 % spending was less than 500 and in 15 % spent over 
4500. In 53% of the families the expenditure with support therapy is higher than 
the median household income in Brazil (R$ 1,211.33). cOnclusiOns: Our results 
were in agreement with literature considering gender, age at diagnosis, frequency 
of food allergy and use of antipsychotics. Support therapy for these children can be 
higher than the median household income in Brazil.
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Objectives: To assess the impact of baseline characteristics, including prior year 
adherence and use of paliperidone palmitate (PP), on AP continuity metric perfor-
mance. MethOds: Medicaid health care claims data from five states (2008-2011) 
were used to identify patients 25-64 years of age diagnosed with schizophrenia and 
≥ 1 AP Rx in baseline year 2010 (BY) and in measurement year 2011 (MY). Adherence 
to AP was defined as the percentage with dispensed AP medication covering ≥ 80% 
of a given year. Baseline year characteristics including demographics, health care 
costs, AP treatment and adherence status were evaluated as potential predictive 
factors of MY continuity using multivariate logistic analyses. Two mutually exclusive 
cohorts (patients with any PP claim vs. all other AP patients in BY) were compared 
on continuity measure performance using inverse propensity score weighting (IPW), 
with propensity representing the likelihood of PP treatment based on BY charac-
teristics. Results: In the study population of 12,990 AP users, 48.6% successfully 
achieved the AP continuity criteria in MY. After controlling for other covariates, the 
likelihood of continuity measure success was improved by adherence in BY (odds 
Objectives: To examine the economic burden and health care utilizations of 
depression patients in the U.S. veteran population. MethOds: Patients diagnosed 
with depression were identified (International Classification of Disease, 9th Revision, 
Clinical Modification [ICD-9-CM] diagnosis codes 296.2x, 296.3x, 300.4, 301.13, 309.0x 
and 311.xx) using the Veterans Health Administration (VHA) Medical SAS datasets 
from October 1, 2007 through September 30, 2012. The initial diagnosis date was 
designated as the index date. A comparison cohort was created for patients with-
out a depression diagnosis, using 1:1 propensity score matching to control for age, 
region, gender, index year and baseline Charlson Comorbidity Index score. For the 
comparison cohort, the index date was randomly chosen to minimize selection bias. 
Patients in both cohorts were required to be at least age 18 years, and have continu-
ous medical and pharmacy benefits 1 year pre- and 1 year post-index date. Study 
outcomes (health care costs, utilizations) were compared between the disease and 
comparator cohorts, based on the matched sample. Results: After 1:1 matching, a 
total of 614,093 patients were identified in each group, and baseline characteristics 
were well-balanced. Patients diagnosed with depression were more likely to have 
inpatient stays (12.73% vs. 2.09%, p< 0.0001) and emergency room (ER) (18.64% vs. 
6.24%, p< 0.0001), physician office (99.59% vs. 54.08%, p< 0.0001), outpatient (99.70% 
vs. 54.83%, p< 0.0001) and pharmacy visits (90.49% vs. 52.20%, p< 0.0001). Higher 
all-cause inpatient stay ($4,017 vs. $599, p< 0.0001), ER visit ($199 vs. $55, p< 0.0001), 
physician office visit ($4,034 vs. $1,152, p< 0.0001), total outpatient ($4,477 vs. $1,304, 
p< 0.0001), pharmacy ($724 vs. $327, p< 0.0001) and total health care costs ($9,218 vs. 
$2,230, p< 0.0001) were also observed for depression patients relative to comparator 
patients. cOnclusiOns: During a period of 12 months, VHA patients diagnosed 
with depression reported higher health care utilization and costs than matched 
control patients.
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Objectives: To understand key economic risk factors that are associated with the 
following mental health conditions for former regular forces personnel who had 
served with the Canadian army. These health conditions include mood disorders, 
depression, anxiety, post-traumatic stress disorder (PTSD) and combined mental 
health status of all four conditions. MethOds: Using different forms of regression 
analysis of cross-sectional data obtained from a survey conducted by Statistics 
Canada in 2010-11 of former army forces personnel. Key risk categories were iden-
tified from economic theory and include educational attainment, military career 
characteristics, behavioural characteristics, income and demographic characteris-
tics. Regression analysis conducted included ordinary-least squared regression, logit 
and probit analysis. In addition, various diagnostic tests were conducted to ensure 
the robustness of econometric models. Results: The results showed that higher-
earning personnel had a significantly lower risk of mental health conditions than 
lower-earning personnel. Obesity significantly increases the risk of mental health 
conditions. Younger former personnel had a significantly greater risk of mental 
health conditions than their older counterparts. Another significant association was 
gender where female personnel showed a greater risk of mental health disorders. 
Deployment for extended periods outside Canada was also shown to be significantly 
associated with increased risk. Rank within the military and the branch of deploy-
ment did not show a significant association with increased risk. The results also 
showed that the higher the educational attainment, the lower the risk of mental 
health conditions though this result was not significant. Significance was set at the 
5% level. cOnclusiOns: This study is the first comprehensive analysis of economic 
risk factors associated with mental health conditions of former army personnel in 
Canada. The results aligned with established economic theory. Additional analysis to 
understand the underlying reasons shown in these results and policy implications 
will be investigated in the presentation.
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Objectives: To describe estimated health resource (HR) and criminal justice (CJ) 
system costs for patients with schizophrenia recently released from incarceration 
that are participating in a clinical trial. MethOds: Interim baseline HR and CJ events 
collected via a resource use questionnaire from a clinical study of individuals with 
schizophrenia recently released from incarceration were analyzed. HR and CJ utiliza-
tion were evaluated for the most recent CJ event prior to study enrollment, the time 
between this CJ event and enrollment, and the year prior to this CJ event (pre-period). 
HR and CJ cost estimates were obtained from administrative claims and published 
literature then applied to the utilization data pro-rated to 365 days. Costs were sum-
marized descriptively using a state government payer perspective and presented in 
2011 US dollars. Results: Mean total cost (n= 422) in the year prior to enrollment 
was $28,631(SD $20,680; Median $23,445). Mean cost of the qualifying CJ event was 
$14,824 (SD $14,846; Median $10,819). The top 3 most frequent CJ qualifying events 
were parole/probation violation, drug charges, and disorderly conduct/vagrancy/pub-
lic intoxication. Average duration of observation for time periods before and after the 
qualifying CJ event was 243 days (SD 103) and 66 days (SD 72), respectively. Estimated 
mean HR cost in the period prior to CJ qualifying event (pre-period) was $2,485 (SD 
$4,959; Median $929), and mean CJ cost was $6,668 (SD $12,401; Median $0). Among 
those with at least one CJ event in the pre-period (n= 183), average CJ cost was $15,376 
(SD $14,870; Median $11,095). Mean HR cost between the CJ event and enrollment was 
$2,030 (SD $3,452; Median $846). cOnclusiOns: From a state government perspec-
tive, mental health related HR and CJ contacts are costly and are potentially avoidable. 
These data can be used to model HR and CJ costs in a population with schizophrenia.
